Basel, Switzerland – The past two years have seen a pair of new treatments approved for a particularly intractable neurodegenerative disease—amyotrophic lateral sclerosis. But while Amylyx’s Relyvrio and Biogen’s Qalsody have crossed the FDA finish line, others have stumbled in a regulatory space that experts say is still evolving. The...
treatment News
NEW HAVEN, Conn. — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced the completion of patient enrollment in the safety lead-in portion of the investigator-sponsored Phase 2 trial of BXCL701 in combination with KEYTRUDA® (pembrolizumab) in previously treated metastatic...
NEW HAVEN, Conn. — BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that the United States Patent and Trademark Office (USPTO) has allowed U.S. Patent Application No. 17/496,470 with claims pertaining to a method of treating agitation in patients...
Barcelona, Spain – Bladder cancer has one of the highest incidence rates in the world and ranks as the fourth most common tumour in men. Despite its relatively low mortality rate, nearly half of bladder tumours resurface within 5 years, requiring ongoing patient monitoring. Frequent hospital visits and the need...
MORGANTOWN, W.Va. — The Blanchette Rockefeller Neurosciences Institute (BRNI) and Inverness Medical Innovations, Inc. (Inverness, NYSE: IMA) of Waltham, Massachusetts, a global leader in rapid diagnostics and health management, announced today that they will work together to further develop and commercialize a diagnostic test for Alzheimer’s disease first discovered by...
Consolidation therapy with blinatumomab was found to improve event-free survival and have less toxicity than chemotherapy in children with high-risk, first-relapse B-cell acute lymphoblastic leukemia (B-ALL), according to the results of a phase 3 trial (ClinicalTrials.gov Identifier: NCT02393859). The trial results were recently reported in JAMA. The trial enrolled 108 children with...
THOUSAND OAKS, Calif. – Amgen (NASDAQ:AMGN) today announced that data from a multicenter, randomized Phase 3 study evaluating the efficacy, safety and tolerability of BLINCYTO® (blinatumomab) compared with consolidation chemotherapy before allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL) were published...
Since its early days in the mid-2000s, optogenetics, with its potential to activate neurons with light, emerged as a promising technique for restoring vision in blind patients. In recent years, at least two companies have announced the start of clinical trials to test optogenetics-based therapies in humans, and one of...
Carlene Knight would love to do things that most people take for granted, such as read books, drive a car, ride a bike, gaze at animals in a zoo and watch movies. She also longs to see expressions on people’s faces. “To be able to see my granddaughter especially —...
North Chicago, Illinois — BLR Bio, an emerging biotechnology company in Rosalind Franklin University’s Helix 51 biomedical incubator, announced that the U.S. Food and Drug Administration (FDA) granted an Orphan Drug Designation for its investigational therapy BLR-200 for the treatment of systemic sclerosis (SSc), also known as scleroderma. Orphan Drug...